Cargando…

A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA

PURPOSE: Breast cancer outcomes are impaired by both delays and disparities in treatment. This study was performed to assess their relationship and to provide a tool to predict patient socioeconomic factors associated with risk for delay. METHODS: The National Cancer Database was reviewed between 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Verdone, Christopher G., Bayron, Jennifer A., Chang, Cecilia, Wang, Chihsiung E., Sigurdson, Elin R., Aggon, Allison A., Porpiglia, Andrea, Hill, Maureen V., Pronovost, Mary T., Bleicher, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747888/
https://www.ncbi.nlm.nih.gov/pubmed/35013916
http://dx.doi.org/10.1007/s10549-021-06460-9
_version_ 1784630938116816896
author Verdone, Christopher G.
Bayron, Jennifer A.
Chang, Cecilia
Wang, Chihsiung E.
Sigurdson, Elin R.
Aggon, Allison A.
Porpiglia, Andrea
Hill, Maureen V.
Pronovost, Mary T.
Bleicher, Richard J.
author_facet Verdone, Christopher G.
Bayron, Jennifer A.
Chang, Cecilia
Wang, Chihsiung E.
Sigurdson, Elin R.
Aggon, Allison A.
Porpiglia, Andrea
Hill, Maureen V.
Pronovost, Mary T.
Bleicher, Richard J.
author_sort Verdone, Christopher G.
collection PubMed
description PURPOSE: Breast cancer outcomes are impaired by both delays and disparities in treatment. This study was performed to assess their relationship and to provide a tool to predict patient socioeconomic factors associated with risk for delay. METHODS: The National Cancer Database was reviewed between 2004 and 2017 for patients with non-metastatic breast cancer managed with upfront surgery. Times to treatment were measured from the date of diagnosis. Patient, tumor, and treatment factors were assessed with attention paid to sociodemographic variables. RESULTS: 514,187 patients remained after exclusions, with 84.3% White, 10.8% Black, 3.7% Asian, and Hispanics comprising 5.6% of the cohort. Medicaid and uninsured patients had longer mean adjusted time to surgery (≥ 46 days) versus private (36.7 days), Medicare (35.9 days), or other governmental insurance (39.8 days). After adjustment, Black race and Hispanic ethnicity were most impactful, adding 6.0 and 6.4 preoperative days, 10.9 and 11.5 days to chemotherapy, 11.1 and 9.1 days to radiation, and 12.5 and 8.9 days to endocrine therapy, respectively. Income, education, and insurance, among other factors, also affected delay. A nomogram, including race and sociodemographic factors, was created to predict the risk of preoperative delay. CONCLUSION:  Significant disparities exist in timeliness of care for factors, including but not limited to, race and ethnicity. Although exact causes cannot be discerned, these data indicate population subsets whose intervals of care risk being longer than those specified by national quality standards. The nomogram created here may help direct resources to those at highest risk of incurring a treatment delay. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06460-9.
format Online
Article
Text
id pubmed-8747888
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87478882022-01-11 A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA Verdone, Christopher G. Bayron, Jennifer A. Chang, Cecilia Wang, Chihsiung E. Sigurdson, Elin R. Aggon, Allison A. Porpiglia, Andrea Hill, Maureen V. Pronovost, Mary T. Bleicher, Richard J. Breast Cancer Res Treat Preclinical Study PURPOSE: Breast cancer outcomes are impaired by both delays and disparities in treatment. This study was performed to assess their relationship and to provide a tool to predict patient socioeconomic factors associated with risk for delay. METHODS: The National Cancer Database was reviewed between 2004 and 2017 for patients with non-metastatic breast cancer managed with upfront surgery. Times to treatment were measured from the date of diagnosis. Patient, tumor, and treatment factors were assessed with attention paid to sociodemographic variables. RESULTS: 514,187 patients remained after exclusions, with 84.3% White, 10.8% Black, 3.7% Asian, and Hispanics comprising 5.6% of the cohort. Medicaid and uninsured patients had longer mean adjusted time to surgery (≥ 46 days) versus private (36.7 days), Medicare (35.9 days), or other governmental insurance (39.8 days). After adjustment, Black race and Hispanic ethnicity were most impactful, adding 6.0 and 6.4 preoperative days, 10.9 and 11.5 days to chemotherapy, 11.1 and 9.1 days to radiation, and 12.5 and 8.9 days to endocrine therapy, respectively. Income, education, and insurance, among other factors, also affected delay. A nomogram, including race and sociodemographic factors, was created to predict the risk of preoperative delay. CONCLUSION:  Significant disparities exist in timeliness of care for factors, including but not limited to, race and ethnicity. Although exact causes cannot be discerned, these data indicate population subsets whose intervals of care risk being longer than those specified by national quality standards. The nomogram created here may help direct resources to those at highest risk of incurring a treatment delay. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06460-9. Springer US 2022-01-11 2022 /pmc/articles/PMC8747888/ /pubmed/35013916 http://dx.doi.org/10.1007/s10549-021-06460-9 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Preclinical Study
Verdone, Christopher G.
Bayron, Jennifer A.
Chang, Cecilia
Wang, Chihsiung E.
Sigurdson, Elin R.
Aggon, Allison A.
Porpiglia, Andrea
Hill, Maureen V.
Pronovost, Mary T.
Bleicher, Richard J.
A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
title A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
title_full A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
title_fullStr A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
title_full_unstemmed A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
title_short A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
title_sort tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the usa
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747888/
https://www.ncbi.nlm.nih.gov/pubmed/35013916
http://dx.doi.org/10.1007/s10549-021-06460-9
work_keys_str_mv AT verdonechristopherg atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT bayronjennifera atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT changcecilia atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT wangchihsiunge atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT sigurdsonelinr atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT aggonallisona atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT porpigliaandrea atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT hillmaureenv atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT pronovostmaryt atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT bleicherrichardj atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT verdonechristopherg tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT bayronjennifera tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT changcecilia tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT wangchihsiunge tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT sigurdsonelinr tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT aggonallisona tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT porpigliaandrea tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT hillmaureenv tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT pronovostmaryt tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa
AT bleicherrichardj tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa